Question explored with the scientific record
Conversation so far
- 1 Stage 0 melanoma in a mole vs not in mole + a private exchange
- 2 Stage 0 melanoma in a mole vs not in mole life expectancy difference + a private exchange
- 3 Stage 0 melanoma life expectancy difference + a private exchange
- 4 Stage 0 melanoma life expectancy when from 60 years + a private exchange
- 5 Do people who have Stage 0 melanoma removed typically die from melanoma?
- 6 Cuma cuma
Answered on this page ↓
Cuma cuma
The short version: I can't tell what "Cuma cuma" means, and I won't guess at a question and answer it as if you asked it.
If you meant to ask something more about stage 0 melanoma after removal, say it in plain words and I'll answer that. If "Cuma cuma" is a typo, a phrase in another language, or a message that got cut off, tell me what you were trying to ask.
One thing I can add without guessing: nothing in this turn's records changes what I said before. The studies here are about melanoma staging, biomarkers, and treatment of later-stage disease, not about long-term death rates after removing stage 0 lesions [1][2][3]. So the honest position stands: after complete removal of stage 0 melanoma, death from melanoma is uncommon, and the mechanism explains why. But that is a moderate-confidence call resting on small surgical series, not on a registry that followed thousands of stage 0 patients for decades.
My call: I don't have a question to answer yet. Rephrase it and I will. Confidence: not clear.
Sources used 3
-
Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
The ESMO Clinical Practice Guidelines for melanoma provide comprehensive recommendations for the diagnosis, treatment, and follow-up of melanoma patients, emphasizing the importance of early detection and tailored therapeutic approaches based on disease stage.
DOI: 10.1093/annonc/mdq188 -
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
A multicentre, randomized, double-blind phase 2 trial (IMMUNED) shows adjuvant nivolumab plus ipilimumab markedly improves recurrence-free survival and overall survival versus placebo in patients with resected stage IV melanoma with no evidence of disease, while nivolumab alone …
DOI: 10.1016/S0140-6736(22)01654-3 -
Melanoma of the nail apparatus: a systematic review and meta‐analysis of current challenges and prognosis
This is a systematic review and meta-analysis of nail apparatus melanoma (NAM) synthesizing 30 studies (n ≈ 1,340 cases) to quantify prognosis and evaluate surgical management, finding a pooled mortality rate of 4.6 per 100 patient-years (5-year survival ~77%) and a progression …
DOI: 10.1111/jdv.16121